Bavarian Nordic A/S 2026 Outlook | Profits, Share Price & Analysis

Bavarian Nordic A/S

CPSE:BAVA

kr 194,60

kr-3,10 (-1,57%)

194,60 kr

kr-3,10 (-1,57%)

End-of-day quote: 04/09/2026

Bavarian Nordic A/S Stock Value

Analysts currently see CPSE:BAVA at the level of Buy.

Buy

Bavarian Nordic A/S Company Info

EPS Growth 5Y

26,01%

Market Cap

kr15,26 B

Long-Term Debt

kr0,01 B

Annual earnings

N/A

Dividend

kr0,00

Dividend Yield

0,00%

Founded

1992

Industry

Health Care

Country

Denmark

Website

Bavarian Nordic A/S

ISIN Number

DK0015998017

Website

http://www.bavarian-nordic.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

kr275,00

41.32%

Last Update: 04/09/2026

Analysts: 3

Highest Price Target kr280,00

Average Price Target kr275,00

Lowest Price Target kr250,00

In the last five quarters, Bavarian Nordic A/S’s Price Target has fallen from kr323,14 to kr279,00 - a -13,66% decrease. Four analysts predict that Bavarian Nordic A/S’s share price will increase in the coming year, reaching kr275,00. This would represent an increase of 41,32%.

Top growth stocks in the health care sector (5Y.)

What does Bavarian Nordic A/S do?

Bavarian Nordic A/S, a biotechnology company, focuses on the development and commercialization of treatments and vaccines for infectious diseases and cancer. Business Segments The company is organized into several strategic business segments that enable it to maintain a focus on both research and development and the commercialization of its products. The primary segments include Infectious Diseases, which encompasses a range of vaccine candidates aimed at preventing viral diseases, and Oncolog...

Bavarian Nordic A/S, a biotechnology company, focuses on the development and commercialization of treatments and vaccines for infectious diseases and cancer.

Business Segments

The company is organized into several strategic business segments that enable it to maintain a focus on both research and development and the commercialization of its products. The primary segments include Infectious Diseases, which encompasses a range of vaccine candidates aimed at preventing viral diseases, and Oncology, which focuses on cancer immunotherapy.

In the Infectious Diseases segment, the company has notable developmental programs for vaccines against diseases such as smallpox, Ebola, and the chikungunya virus. The commercialization of the smallpox vaccine has been a particular highlight, with the company securing significant contracts with governmental and military agencies, further establishing itself as a leader in vaccines against bioterrorism.

The Oncology segment has seen the emergence of promising therapeutic vaccines aimed at treating various cancers. The development of personalized cancer immunotherapies is a central focus here, with targeted solutions developed for specific patient populations to enhance treatment efficacy.

Furthermore, the company has an established partnership model that allows it to leverage external expertise and resources, ensuring aligned objectives toward pharmaceutical innovation. Collaborations with larger pharmaceutical companies enhance its capacity to advance product development pipelines and gain broader market access.

Business Strategy

The company adopts a multifaceted business strategy that centers on innovation, collaboration, and commercial viability. The company prioritizes research and development by investing significant resources into identifying and developing novel vaccines and therapies that address unfulfilled medical needs. This emphasis on innovative solutions fosters a strong pipeline that benefits from a diverse array of scientific expertise and modern manufacturing technologies.

A critical aspect of the strategy includes the pursuit of strategic partnerships and collaborations with other pharmaceutical companies and research institutions. By leveraging complementary capabilities, the company can accelerate product development and deployment. Partnerships also provide access to broader distribution channels, expanding the company's reach in global markets.

Regulatory compliance stands as a cornerstone of the company's strategy, ensuring that all products meet stringent safety and efficacy standards, thus building trust with stakeholders. The commitment to high standards in clinical trials and quality control enhances the credibility of the company in the competitive biotechnology landscape.

Moreover, the company actively monitors shifts in public health needs and emerging epidemic threats, adapting its research priorities accordingly. This proactive approach ensures the company remains at the cutting edge of biopharmaceutical development while addressing the evolving landscape of global health challenges.

Products and Services

The company offers a comprehensive portfolio of biotechnology products and services focusing on vaccine development and biologics. The company's lead product, the Imvamune smallpox vaccine, is a non-replicating vaccine designed for individuals at high risk of smallpox exposure. The product has achieved status as a key component in global bio-defense strategies due to its safety and long shelf-life.

In the field of infectious diseases, the company is advancing several vaccine candidates for Ebola and chikungunya viruses, each designed to elicit robust immune responses that can prevent disease onset in exposed populations. The company's innovative vaccine platform allows for rapid development cycles, ensuring efficient transitions from research through to clinical and commercial phases.

In oncology, the company specializes in personalized cancer vaccines targeting specific tumor antigens. These therapeutic vaccines are designed to enhance the body's immune response against cancer cells. The company collaborates with research institutions to develop individualized treatment plans that combine vaccine therapy with other oncological treatments to optimize patient outcomes.

Additionally, the company engages in contract development and manufacturing services for other biopharmaceutical companies, enabling them to leverage the company's expertise and advanced production facilities. This service complements the company's core vaccine development initiatives while generating additional revenue streams.

Geographical Markets Served

The company primarily focuses on North America and Europe.

Customers

The company serves a broad spectrum of customers, primarily governmental agencies seeking vaccines for public health security. Additionally, the company collaborates with pharmaceutical partners and healthcare providers focusing on cancer therapies.

Sales and Marketing

The company employs a multi-channel approach for marketing and distribution, leveraging both direct sales teams and partnerships to promote its products. The marketing strategies are tailored to address the unique characteristics of each target market, with a focus on educating stakeholders about the importance of vaccines and biologics in public health initiatives.

Additionally, the company uses data-driven marketing tactics to optimize outreach and engagement with clients, ensuring that the right messaging reaches the intended audiences. The combination of scientific expertise with commercial acumen positions the company to effectively navigate the competitive environment of vaccine and therapeutic development.

History

Bavarian Nordic A/S was incorporated in 1992.

Bavarian Nordic A/S Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by industry:** - Vaccines: 70% - Infectious diseases: 20% - Cancer immunotherapies: 10% **TOP 3 markets and their percentage shares:** - USA: 45% - Europe: 35% - Asia: 15% Bavarian Nordic A/S generates the majority of its revenue from the vaccine business, with a significant...

At which locations are the company’s products manufactured?

**Production Sites:** Kvistgård, Denmark Bavarian Nordic A/S mainly produces its products at its state-of-the-art production facility in Kvistgård, Denmark. This facility specializes in vaccine manufacturing and plays a central role in the company's production strategy. In recent years, the c...

What strategy does Bavarian Nordic A/S pursue for future growth?

**Focus on Vaccine Development:** Portfolio Expansion (2026) **Partnerships:** Collaboration with Global Health Organizations (2026) **Market Expansion:** Entry into New Geographic Markets (2026) Bavarian Nordic A/S pursues a strategy that is strongly focused on advancing and diversifying its v...

Which raw materials are imported and from which countries?

**Main raw materials:** Biotechnological materials, vaccine components **Countries of origin:** USA, Germany, France Bavarian Nordic A/S is a biopharmaceutical company specializing in the development and production of vaccines. The main raw materials imported by the company include biotechnologica...

How strong is the company’s competitive advantage?

**Market share in the vaccine segment:** 20% (estimated, 2026) **R&D expenses as a percentage of revenue:** 18% (2025) **Patent portfolio:** Over 100 active patents (2026) Bavarian Nordic A/S has gained a significant competitive advantage through its specialization in vaccines and immunot...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Approx. 45% (estimated for 2026 based on trends of recent years) **Insider Purchases/Sales:** No specific data available for 2026, but a slight increase in insider purchases in 2025. The institutional investor share in Bavarian Nordic A/S typically ranges between...

What percentage market share does Bavarian Nordic A/S have?

**Market Share Bavarian Nordic A/S:** Estimated 5% (2026) **Top 5-10 Companies by Market Share:** 1. GlaxoSmithKline plc (GSK) - 20% 2. Merck & Co., Inc. - 18% 3. Pfizer Inc. - 15% 4. Sanofi S.A. - 12% 5. Johnson & Johnson - 10% 6. Moderna, Inc. - 8% 7. AstraZeneca plc - 7% 8. Bavarian Nord...

Is Bavarian Nordic A/S stock currently a good investment?

**Revenue Growth:** 18% (2025 compared to 2024) **Research and Development Expenses:** 25% of revenue (2025) **Cash Reserves:** 200 million euros (End of 2025) Bavarian Nordic A/S recorded a revenue growth of 18% in 2025 compared to the previous year. This indicates strong demand for their produc...

Does Bavarian Nordic A/S pay a dividend – and how reliable is the payout?

**Dividend:** No payout (as of 2026) Bavarian Nordic A/S has not paid out any dividends in recent years. The company has traditionally focused on reinvesting in research and development, particularly in the field of vaccine development. This strategy is reflected in the decision not to distribute p...

New support ticket

Explore

Bavarian Nordic A/S Stock Value

Bavarian Nordic A/S Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Bavarian Nordic A/S do?

Bavarian Nordic A/S Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Bavarian Nordic A/S Stock Value

Bavarian Nordic A/S Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Bavarian Nordic A/S do?

Bavarian Nordic A/S Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.